本公司及董事会全体成员保证公告内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 英科医疗科技股份有限公司（以下简称"公司"）于近日接到公 司控股股东刘方毅先生的通知，获悉刘方毅先生将其所持有的公司部 分股份办理了质押解除手续。现将具体内容公告如下： 注：本公告总股本数以截至 2025 年 11 月 11 日公司最新总股本 654,793,743 股为计算标 准。 证券代码：300677 证券简称：英科医疗 公告编号：2025-153 英科医疗科技股份有限公司 关于控股股东部分股份解除质押的公告 二、股东股份累计质押的情况 三、其他说明 控股股东刘方毅先生资信状况良好，具备良好的资金偿还能力， 本次解除质押后，其剩余质押股份不存在实质性资金偿还风险，所质 押的股份目前不存在平仓风险或被强制过户的情形，质押风险可控， 不会对公司生产经营、公司治理等产生影响。公司将持续关注其质押 情况及质押风险情况，并按规定及时做好相关信息披露工作，敬请投 资者注意投资风险。 四、备查文件 1、中国证券登记结算有限责任公司深圳分公司证券质押及司法 冻结明细表； 2、国金证券股份有限公司股票质押式回购交易协议书。 特此公 ...

Core Viewpoint - Inke Medical's stock price has shown significant growth this year, with a year-to-date increase of 64.94%, reflecting strong market performance and investor interest [1][2]. Financial Performance - For the period from January to September 2025, Inke Medical reported a revenue of 7.425 billion yuan, representing a year-on-year growth of 4.60% [2]. - The net profit attributable to shareholders for the same period was 924 million yuan, marking a substantial increase of 34.47% compared to the previous year [2]. Stock Market Activity - As of November 12, Inke Medical's stock price reached 41.45 yuan per share, with a trading volume of 230 million yuan and a market capitalization of 27.141 billion yuan [1]. - The stock experienced a net inflow of 15.9098 million yuan from institutional investors, indicating positive sentiment [1]. Shareholder Structure - As of September 30, 2025, the number of shareholders for Inke Medical decreased by 21.11% to 47,300, while the average number of shares held per shareholder increased by 25.65% to 9,832 shares [2][4]. - The top circulating shareholders include various ETFs and mutual funds, with notable changes in holdings among major investors [4]. Dividend Distribution - Inke Medical has distributed a total of 1.903 billion yuan in dividends since its A-share listing, with 245 million yuan distributed over the past three years [3].

Investment Rating - The investment rating for the company is "Buy" and it is maintained [1] Core Views - The company is gradually showing signs of an industry turning point and is progressing towards becoming a global leader in nitrile gloves [4] - For the first three quarters of 2025, the company achieved operating revenue of 7.425 billion yuan, a year-on-year increase of 4.60%, and a net profit attributable to the parent company of 924 million yuan, a year-on-year increase of 34.47% [4] - The company has a leading position in the disposable glove market, with an annual production capacity of 87 billion gloves, including 56 billion nitrile gloves and 31 billion PVC gloves [5] Company Overview - Latest closing price: 38.69 yuan - Total shares/ circulating shares: 655 million / 466 million - Total market value/ circulating market value: 25.3 billion yuan / 18 billion yuan - 52-week high/low price: 45.50 / 20.71 - Debt-to-asset ratio: 48.9% - Price-to-earnings ratio: 17.12 - Largest shareholder: Liu Fangyi [3] Financial Performance - In Q3 2025, the company achieved operating revenue of 2.511 billion yuan, a year-on-year decrease of 2.90%, and a net profit attributable to the parent company of 214 million yuan, a year-on-year increase of 113.04% [4] - The company is expected to achieve revenues of 9.928 billion yuan, 12.328 billion yuan, and 15.400 billion yuan for 2025, 2026, and 2027 respectively, with year-on-year growth rates of 4.25%, 24.18%, and 24.92% [6] - The projected net profit attributable to the parent company for 2025-2027 is 1.270 billion yuan, 2.043 billion yuan, and 3.091 billion yuan, with year-on-year growth rates of -13.37%, 60.94%, and 51.28% [6] Market Positioning - The company has strengthened its brand marketing in the domestic market, successfully entering high-end supermarkets and achieving top rankings in e-commerce during promotional events [5] - The company has signed a strategic cooperation agreement with JD Health to explore innovative service models in "Internet + healthcare" [5]

Group 1 - The core point of the article is that Yingke Medical's stock price increased by 5.3% to 40.74 CNY per share, with a trading volume of 445 million CNY and a turnover rate of 2.39%, resulting in a total market capitalization of 26.676 billion CNY [1] - Yingke Medical, established on July 20, 2009, and listed on July 21, 2017, operates in three main business segments: personal protection (91.47% of revenue), rehabilitation care (4.75%), and other products (3.77%) [1] - The top circulating shareholder of Yingke Medical is Huabao Fund, which reduced its holdings in the Huabao Zhongzheng Medical ETF by 2.2149 million shares, now holding 12.8002 million shares, representing 2.75% of circulating shares [2] Group 2 - The Huabao Zhongzheng Medical ETF, managed by Hu Jie, has a total asset size of 100.204 billion CNY, with a best fund return of 182.37% and a worst return of -98.01% during Hu Jie's tenure [3] - The Huabao Zhongzheng Medical ETF was established on May 20, 2019, with a latest scale of 26.404 billion CNY, achieving a year-to-date return of 10.25% and a one-year loss of 1.07% [2]

Industry Overview - Rehabilitation devices are defined as medical equipment or assistive tools used in rehabilitation to assess, train, and treat patients, helping them improve functionality and recover bodily functions or compensate for deficiencies [1] - The rehabilitation device industry can be categorized into rehabilitation medical aids, rehabilitation therapy equipment, rehabilitation training devices, and assessment instruments [1] Industry Chain Analysis - The upstream of the rehabilitation medical device industry mainly consists of raw materials and software systems, with raw materials being the core element affecting product quality and manufacturing efficiency [2] - The midstream involves the production of rehabilitation assessment instruments, training devices, therapy equipment, and other rehabilitation devices [2] - The downstream consumer segment primarily includes elderly, chronic disease, and disabled groups [2][5] Industry Development History - The Chinese rehabilitation device industry has gone through three stages: initial phase (1980-1989), transformation phase (1990-2011), and rapid growth phase (2012-present), with significant policy support and market expansion in the latter phase [7][8] Policy Background - Recent national policies have promoted high-level standardization and integration of rehabilitation devices with technologies like AI, IoT, and 5G, creating favorable conditions for high-quality industry transformation [10][11] Current Industry Status - The number of registered rehabilitation device products in China has seen explosive growth since 2019, with projections indicating 1,167 registrations by 2024 [14] - The market size for rehabilitation devices in China is expected to reach approximately 21.1 billion yuan in 2024, driven by an aging population and increasing chronic diseases [15] - Rehabilitation aids dominate the market, accounting for 82.15% of the total market size in 2024 [17] - The elderly care segment is projected to account for about 67% of the application structure in 2024 [18] Competitive Landscape - The competitive landscape of the rehabilitation device industry shows a concentration of core manufacturing enterprises in eastern coastal provinces like Jiangsu, Guangdong, and Shandong, while central and western regions focus on raw material supply [21] - The top three companies in the rehabilitation device market by share in 2024 are Kefu Medical, Yuyue Medical, and Xiangyu Medical, with market shares of 6.47%, 6.18%, and 3.51% respectively [24] Future Development Outlook - By 2030, the market size of the rehabilitation device industry is expected to exceed 47 billion yuan, driven by the aging population and increased demand for rehabilitation services [26] - The industry is predicted to grow at a compound annual growth rate (CAGR) of around 14% from 2025 to 2030 [26] Industry Trends - The rehabilitation device industry is experiencing a trend towards smart technology and product diversification, with the integration of AI, IoT, and 3D printing technologies [28] - The aging population and the rise in chronic diseases are expected to sustain the growth of rehabilitation demand, supported by favorable policies and market expansion [28]

Investment Rating - The investment rating for the company is "Buy" and is maintained [1] Core Insights - The company, Yingke Medical, is a leading global supplier of personal protective equipment, particularly disposable gloves, with an annual production capacity of 87 billion pieces [5] - The company reported a revenue of 7.425 billion yuan for the first three quarters of 2025, representing a year-on-year growth of 4.60%, while the net profit attributable to the parent company was 924 million yuan, up 34.47% year-on-year [4] - The company has achieved significant market recognition, being awarded the title of "No. 1 in national sales of disposable gloves" and "No. 1 in national sales of disposable nitrile gloves" [5] Financial Performance - For Q3 2025, the company reported a revenue of 2.511 billion yuan, a decrease of 2.90% year-on-year, but the net profit attributable to the parent company increased by 113.04% to 214 million yuan [4] - The projected revenues for 2025, 2026, and 2027 are 9.928 billion yuan, 12.328 billion yuan, and 15.400 billion yuan, with year-on-year growth rates of 4.25%, 24.18%, and 24.92% respectively [6] - The projected net profit attributable to the parent company for the same years is 1.270 billion yuan, 2.043 billion yuan, and 3.091 billion yuan, with growth rates of -13.37%, 60.94%, and 51.28% respectively [6] Market Position and Strategy - The company is enhancing its brand marketing efforts in the domestic market, successfully entering high-end retail channels and achieving top rankings in e-commerce during promotional events [5] - The company has established a strategic partnership with JD Health to explore innovative service models in the "Internet + healthcare" space [5]

Core Insights - The company reported a revenue of 7.425 billion yuan for the first three quarters of 2025, representing a year-on-year growth of 4.60% [1] - The net profit attributable to the parent company for the same period was 924 million yuan, showing a significant increase of 34.47% year-on-year [1] - However, the net profit excluding non-recurring gains and losses decreased by 19.32% to 484 million yuan [1] Group 1: Financial Performance - In Q3 2025, the company achieved a revenue of 2.511 billion yuan, which is a decline of 2.90% year-on-year [1] - The net profit attributable to the parent company in Q3 was 214 million yuan, marking a substantial increase of 113.04% year-on-year [1] - The net profit excluding non-recurring gains and losses for Q3 was 84 million yuan, reflecting a decrease of 25.87% year-on-year [1] Group 2: Market Position and Strategy - The company is a leading global supplier of personal protective equipment, particularly disposable gloves, with an annual production capacity of 87 billion pieces [2] - The company has been recognized as the top seller of disposable gloves and nitrile gloves in China by a prominent market research firm [2] - The company is enhancing its brand marketing efforts in the domestic market, successfully entering high-end retail channels and achieving top sales rankings during promotional events [2] Group 3: Revenue Forecast - Revenue projections for 2025 to 2027 are 9.928 billion yuan, 12.328 billion yuan, and 15.400 billion yuan, with year-on-year growth rates of 4.25%, 24.18%, and 24.92% respectively [3] - Expected net profit attributable to the parent company for the same period is 1.270 billion yuan, 2.043 billion yuan, and 3.091 billion yuan, with year-on-year growth rates of -13.37%, 60.94%, and 51.28% respectively [3] - The projected price-to-earnings (PE) ratios for 2025 to 2027 are 20.19, 12.55, and 8.29, while the price-to-earnings growth (PEG) ratios are -1.51, 0.21, and 0.16 [3]

证券代码：300677 证券简称：英科医疗 公告编号：2025-152 英科医疗科技股份有限公司 关于为子公司提供担保事项的进展公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 英科医疗科技股份有限公司（以下简称"公司"）于 2025 年 4 月 23 日、2025 年 5 月 26 日分别召开的第四届董事会第二次（定期） 会议、第四届监事会第二次（定期）会议以及 2024 年度股东大会， 审议通过了《关于公司及子公司向银行申请授信额度及担保事项的议 案》。为满足公司及子公司的生产经营需要，公司及子公司拟向银行 等金融机构申请综合授信的额度以及金融衍生品交易风险限额的总 额（以下简称"授信额度"）不超过 360 亿元人民币，对其担保总额 不超过 360 亿元人民币，授权期限自公司 2024 年度股东大会审议通 过之日起至下一年度股东大会召开时止。具体内容详见刊登于巨潮资 讯网（www.cninfo.com.cn）的《关于公司及子公司向银行申请授信额 度及担保事项的公告》《2024 年度股东大会决议公告》（公告编号： 2025-046、2025-072）。 一、担 ...

Core Insights - The stock of Yingke Medical (300677) closed at 38.56 yuan on November 6, 2025, down 1.51% with a turnover rate of 2.19% and a trading volume of 101,900 hands, resulting in a transaction value of 393 million yuan [1] - The net outflow of main funds was 26.21 million yuan, accounting for 6.67% of the total transaction value, while retail investors saw a net inflow of 33.84 million yuan, representing 8.61% of the total transaction value [1][2] Financial Performance - For the first three quarters of 2025, Yingke Medical reported a main revenue of 7.425 billion yuan, an increase of 4.6% year-on-year, and a net profit attributable to shareholders of 924 million yuan, up 34.47% year-on-year [3] - The third quarter of 2025 saw a single-quarter main revenue of 2.511 billion yuan, a decrease of 2.9% year-on-year, while the single-quarter net profit attributable to shareholders was 214 million yuan, an increase of 113.04% year-on-year [3] - The company’s gross profit margin stood at 23.7%, with a net profit margin of 12.82% [3] Market Position - Yingke Medical has a total market capitalization of 25.249 billion yuan, ranking 9th in the medical device industry, with a net asset value of 18.467 billion yuan, ranking 4th [3] - The company’s price-to-earnings ratio (P/E) is 20.49, significantly lower than the industry average of 62.24, indicating a favorable valuation [3] - The company’s return on equity (ROE) is 5.19%, which is considerably higher than the industry average of 0.15% [3] Investment Sentiment - Over the last 90 days, five institutions have given a buy rating for Yingke Medical, indicating positive sentiment among analysts [4]

Core Viewpoint - In recent trading, Yingke Medical's stock price has shown a decline of 2.02%, with a current price of 38.36 CNY per share and a total market capitalization of 25.118 billion CNY. The company has experienced a year-to-date stock price increase of 52.64% [1] Financial Performance - For the period from January to September 2025, Yingke Medical reported a revenue of 7.425 billion CNY, reflecting a year-on-year growth of 4.60%. The net profit attributable to shareholders was 924 million CNY, marking a significant increase of 34.47% compared to the previous year [2] Shareholder Information - As of September 30, 2025, the number of shareholders for Yingke Medical decreased by 21.11% to 47,300. The average number of circulating shares per shareholder increased by 25.65% to 9,832 shares [2] Dividend Distribution - Yingke Medical has cumulatively distributed dividends amounting to 1.903 billion CNY since its A-share listing, with a total of 245 million CNY distributed over the past three years [3] Institutional Holdings - As of September 30, 2025, the top ten circulating shareholders of Yingke Medical include notable ETFs such as Huabao Zhongzheng Medical ETF and Yifangda Growth Enterprise Board ETF, with some shareholders reducing their holdings while others have newly entered [4]